Table 1 Information on signalment, TBEV antibody titers in CSF and serum, and results of CSF analyzis of all dogs (n  =  89) included in the study

Total number of dogs 89

20

36

33

Sex

 Female

12 (60.0%)

15 (41.7%)

8 (24.2%)

 Neutered female

2 (10.0%)

2 (5.6%)

4 (12.1%)

 Male

3 (15.0%)

17 (47.2%)

14 (42.4%)

 Neutered male

3 (15.0%)

2 (5.6%)

7 (21.2%)

Median age (years)

4.9 IQR 2.0–5.5

2.0 IQR 1.0–7.3

10.0 IQR 7.6–12.4

Median body weight (kg)

17.0 IQR 6.0–27.0

11.0 IQR 7.6–21.4

26.0 IQR 9.6–30.8

Median TBEV ab (U/mL) CSF

26.8 IQR 20.2–34.8

18.8 IQR 15.3–27.1

22.4 IQR 16.1–33.4

 Range TBEV ab (U/mL) CSF

2.7–194.3

13.6–115.6

9.6–81.3

Number of dogs with CSF ab  >  126 U/mL

3 (15.0%)

0

0

Median TBEV ab (U/mL) serum

26.3 IQR 20.1–129.3

22.3 IQR 16.2–38.5

40.9 IQR 24.6–76.5

 Range TBEV ab (U/mL) serum

20.1–930.3

16.2–430.7

15.1–171.1

Number of dogs with serum ab > 126 U/mL

5 (25.0%)

4 (11.1%)

2 (6.1%)

Number of dogs with CSF pleocytosis

13 (65.0%)

11 (30.6%)

Not analysed

Median number of leukocytes in CSF

16.0 IQR 2.5–40.5

2.5 IQR 0.0–7.5

Not analysed

Median protein (g/L) in CSF

0.32 IQR 0.18–0.86

0.22 IQR 0.13–0.43

Not analysed